Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kamada Ltd.
Israeli firm Kamada has entered into two agreements for commercialization of three biosimilars in Israel. The company expects to launch the products between 2022 and 2024.
Menarini/Stemline, Supernus/US WorldMeds, BioMarin/DiNOAQOR, Adicet/ResTORbio, Vertex/Affinia, Hansoh/NiKang, plus COVID-19 deals in brief and more.
Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.
Pfenex believes it and commercial partner Alvogen could enjoy an extended period as the only direct competitor to Eli Lilly’s Forteo teriparatide reference brand in the US.
- Drug Delivery
- Drug Discovery Tools
- Large Molecule